ArticlePain research & management2026
Awareness and Prescribing Patterns of Acute and Preventive Migraine Medications Among General Practitioners: The Kawasaki Medical Association Study.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimIn Japan, the introduction of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies and the 5-HT1F receptor agonist lasmiditan has transformed migraine treatment. However, medical consultation and prescription rates for migraine remain low. This study aimed to clarify the awareness and prescribing patterns of acute and preventive migraine medications among physicians in Kawasaki, Japan.
methodsA questionnaire survey of 1274 physicians registered with the Kawasaki Medical Association was conducted from December 2024 to February 2025. Responses were collected via fax or web form, and data were analyzed according to medical specialty.
resultsA total of 288 physicians responded (response rate, 22.6%). General internists accounted for 49.3%, followed by neurologists (5.9%) and neurosurgeons (3.8%). For acute treatment, 65.9% of the respondents primarily prescribed acetaminophen or nonsteroidal anti-inflammatory drugs. Although 87.8% were aware of triptans, only 64.1% prescribed them. Awareness and prescription of lasmiditan and anti-CGRP monoclonal antibodies were particularly low among nonspecialists and were significantly lower than those among specialists (p < 0.008). In the multivariable analysis, specialty was not independently associated with triptan prescribing, whereas specialists were markedly more likely to prescribe anti-CGRP monoclonal antibodies (adjusted OR 42.6).
conclusionIn Kawasaki, awareness and use of new migraine therapies remain limited, especially among nonspecialists. Specialty independently influenced the prescription of anti-CGRP monoclonal antibodies but not triptans, highlighting the need for enhanced education and collaboration with headache specialists to improve migraine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.